Arthneeti

Lactose (India) Share Price & Earnings Call Analysis

₹105.55-4.48% today
Market cap
₹133 Cr
P/E
19.14
ROE
9.81%
PEG
0.27
Price to sales
0.78
Debt to equity
0.96
52W high / low
₹130 / ₹78.2
Sales growth (5Y)
36.11%
EBITDA margin
11.37%
Net profit margin
3.71%
Promoter holding
53.65%
Sales (last year)
₹171 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Lactose (India) rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Lactose (India).

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Lactose (India) announcements

All announcements →

Financials of Lactose (India)

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Lactose (India)

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +25.9927.4724.4332.6029.4029.4630.4528.7227.7739.5841.1836.7745.77
Expenses +21.9923.7021.0426.8823.2823.8825.4425.7524.3635.1135.9233.7140.75
Operating Profit4.003.773.395.726.125.585.012.973.414.475.263.065.02
OPM %15.39%13.72%13.88%17.55%20.82%18.94%16.45%10.34%12.28%11.29%12.77%8.32%10.97%
Other Income +0.140.280.260.280.310.220.300.560.370.410.370.630.22
Interest1.841.551.311.211.171.261.371.641.841.221.041.391.43
Depreciation1.191.191.201.201.631.311.331.351.391.371.441.431.50
Profit before tax1.111.311.143.593.633.232.610.540.552.293.150.872.31
Tax %20.72%26.72%28.95%27.02%33.88%29.72%22.22%59.26%-18.18%34.50%31.11%40.23%18.61%
Net Profit +0.890.960.812.632.402.272.030.220.641.502.160.531.88
EPS in Rs0.710.760.642.091.911.801.610.170.511.191.720.421.49

Financials of Lactose (India)

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +243436314140354666114116163
Expenses +1924242531312934549599145
Operating Profit51011610961211191718
OPM %22%30%32%18%24%23%18%27%17%17%15%11%
Other Income +011100011111
Interest344556556565
Depreciation233444455556
Profit before tax144-310-3311079
Tax %42%28%36%-52%33%30%-24%23%18%30%25%30%
Net Profit +033-110-221756
EPS in Rs0.593.172.87-1.320.710.07-2.171.950.965.394.104.81
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Lactose (India)

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8910101010111313131313
Reserves71217222424242728354652
Borrowings +393734383639464138395762
Other Liabilities +25262413111071022141856
Total Liabilities8083858382848890101101133183
Fixed Assets +626164636062595956555269
CWIP1110104000100
Investments100000110000
Other Assets +1521201920222530454671114
Total Assets8083858382848890101101133183

Financials of Lactose (India)

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +13180572889-06
Cash from Investing Activity +-233-5-2-2-3-6-1-1-2-16-10
Cash from Financing Activity +10-5-34-5-45-8-8-6191
Net Cash Flow-1-0-03-211-0-113-4
Free Cash Flow-10-03-234-3767-14-5
CFO/OP255%18%74%15%58%80%34%68%70%50%5%37%

Financials of Lactose (India)

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days839691636264679069496875
Inventory Days129344440456384471587343344119171217
Days Payable2733405593302422021531952755974146
Cash Conversion Cycle-61100-27188204333501238138109165146
Working Capital Days-118-100-107184259564656262418
ROCE %8%13%15%4%9%8%3%10%9%18%13%11%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals